Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
ALDX.US
id: 792
Aldeyra (ALDX) ADX-2191 Failed NDA Case
The case has been dismissed, typically without any further action.
D. Massachusetts
Court 1:23-cv-11737
Case number03/17/2022
Class period Start06/20/2023
Class period End09/29/2023
Lead Plaintiff motion deadline- FDA stated that there was a lack of effectiveness evidence in NDA for Aldeyra's ADX-2191.
- $ALDX fell over 27%, losing $170 million of its market cap.
- Investors suspect Aldeyra of failing to disclose that the ADX-2191 application did not include adequate investigations.
On June 21, 2023, Aldeyra (ALDX) announced receipt of a CRL from the FDA for the NDA of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL). The press release stated that “although no safety or manufacturing issues with ADX-2191 were identified, the FDA stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations’ in the literature-based NDA submission.
On this news, $ALDX fell over 27%, losing more than $170 million of its market capitalization.
Taking all representations into account, Investors have reasons to suspect Aldeyra and its Accountables of misleading and failing to disclose that the ADX-2191 application did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness.
Case Type
US Securities Class Action
Case Status
Dismissed
Alleged Offence
Misleading Statements,
Failure to Disclose,
Negligence,
Omissions
Suspected Party
Directors,
Management,
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
06/21/2023
Filing date
07/31/2023
Lead Plaintiff Deadline
09/29/2023
Judge
Hon. Denise J. Casper